BPTH Bio-Path Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BPTH

Price (delayed)

$1.57

Market cap

$12.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.97

Enterprise value

-$906,543

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path's lead ...

Highlights
Bio-Path Holdings's debt has decreased by 9% QoQ and by 5% YoY
The quick ratio has plunged by 73% YoY and by 52% from the previous quarter
BPTH's net income has dropped by 58% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biopathholdings.com
Peers: BAX SGEN BMY SPPI

Key stats

What are the main financial stats of BPTH
Market
Shares outstanding
7.96M
Market cap
$12.5M
Enterprise value
-$906,543
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$14.02M
EBITDA
-$13.84M
Free cash flow
-$12.93M
Per share
EPS
-$1.97
Free cash flow per share
-$1.81
Book value per share
$2.26
Revenue per share
$0
TBVPS
$2.59
Balance sheet
Total assets
$18.54M
Total liabilities
$2.34M
Debt
$246,000
Equity
$16.2M
Working capital
$15.94M
Liquidity
Debt to equity
0.02
Current ratio
8.24
Quick ratio
6.2
Net debt/EBITDA
0.97
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-62.2%
Return on equity
-67.2%
Return on invested capital
-590.4%
Return on capital employed
-85.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BPTH stock price

How has the Bio-Path Holdings stock price performed over time
Intraday
-1.66%
1 week
0.64%
1 month
-13.26%
1 year
-57.22%
YTD
3.97%
QTD
3.97%

Financial performance

How have Bio-Path Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.03M
Net income
-$14.02M
Gross margin
N/A
Net margin
N/A
BPTH's net income has dropped by 58% year-on-year and by 12% since the previous quarter
The operating income has dropped by 58% year-on-year and by 12% since the previous quarter

Growth

What is Bio-Path Holdings's growth rate over time

Valuation

What is Bio-Path Holdings stock price valuation
P/E
N/A
P/B
0.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Bio-Path Holdings's EPS has decreased by 27% YoY and by 11% from the previous quarter
The stock's price to book (P/B) is 59% less than its 5-year quarterly average of 1.7 and 47% less than its last 4 quarters average of 1.3
BPTH's equity is down by 45% year-on-year and by 17% since the previous quarter

Efficiency

How efficient is Bio-Path Holdings business performance
The return on equity has dropped by 100% year-on-year and by 29% since the previous quarter
BPTH's return on assets has dropped by 95% year-on-year and by 27% since the previous quarter
BPTH's ROIC is down by 38% YoY and by 15% QoQ

Dividends

What is BPTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BPTH.

Financial health

How did Bio-Path Holdings financials performed over time
Bio-Path Holdings's total liabilities has surged by 76% YoY and by 57% QoQ
The quick ratio has plunged by 73% YoY and by 52% from the previous quarter
Bio-Path Holdings's debt is 98% lower than its equity
The company's debt to equity has surged by 100% QoQ and by 100% YoY
BPTH's equity is down by 45% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.